Tag: Hedgehog pathway inhibitor

In clinical trials for locally advanced basal cell carcinoma (laBCC), the targeted therapy Odomzo (sonidegib) demonstrated an objective response rate of 56% for patients receiving the 200 mg daily dose. Approved by the FDA, **what is Odomzo** and how does this medication work to treat certain types of skin cancer?

Clinical trial data from studies like ERIVANCE show that muscle spasms affect a significant majority of patients, making it the most frequently reported answer to **what is the most common side effect of vismodegib**. Beyond muscle issues, the Hedgehog pathway inhibitor is also commonly associated with hair loss, taste disturbances, fatigue, and weight loss.

Vismodegib, a targeted therapy for advanced basal cell carcinoma (BCC), is typically prescribed as an oral capsule taken once daily. Patients need to understand the specific instructions on **how is vismodegib given** to ensure safe and effective treatment. This article provides general information regarding its oral administration and important precautions.